Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 09926 AKESO, INC. - B > Detailed Quotes

09926 AKESO, INC. - B

Watchlist
38.800
+1.800+4.86%
Closed  12/08 16:08 CCT
High
40.850
Open
38.750
Turnover
1.19B
Low
37.550
Pre Close
37.000
Volume
30.25M
Market Cap
32.63B
P/E(TTM)
Loss
52wk High
43.600
Shares
841.06M
P/E(Static)
Loss
52wk Low
11.500
Float Cap
32.63B
Bid/Ask %
67.75%
Historical High
69.900
Shs Float
841.06M
Volume Ratio
1.70
Historical Low
11.500
Dividend TTM
--
Div Yield TTM
--
P/B
10.70
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
3.60%
Amplitude
8.92%
Avg Price
39.402
Lot Size
1000
Float Cap
32.63B
Bid/Ask %
67.75%
Historical High
69.900
Shs Float
841.06M
Volume Ratio
1.70
Historical Low
11.500
Dividend TTM
--
P/B
10.70
Dividend LFY
--
Turnover Ratio
3.60%
Amplitude
8.92%
Avg Price
39.402
Lot Size
1000
Price Forecast

News

Comment

Company Overview More
Kangfang Biotechnology (Cayman) Co., Ltd. is a biopharmaceutical company dedicated to the research, development, production and commercialization of innovative antibody drugs affordable to patients around the world. Since its inception, the company has established an end-to-end omni-directional drug development platform (ACE platform), covering fully integrated drug discovery and development functions, including target verification, antibody drug discovery and development, CMC production process development and GMP-compliant production. The company has also successfully developed bispecific antibody drug development technology (TETRABODY technology), which helps us overcome three CMC difficulties encountered in the development and production of bispecific antibodies, including inefficient expression levels, process development obstacles, and antibody stability and properties. The company currently has more than 30 innovative drug product lines for the treatment of cancer, autoimmune, inflammation, metabolic diseases and other major diseases, of which 15 varieties have entered the clinical stage, including two international first bispecific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The company hopes to become a leading biopharmaceutical company in the world through efficient and innovative research and development of new drugs of the same kind or the best treatment of the same kind.
CEO: Yu Xia
Market: Hong Kong motherboard
Listing Date: 04/24/2020
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist